A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion
← catalyst calendarSponsored by Eisai Co., Ltd. (industry) · 4523.T — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
63actual
Sites
56
Countries
China, Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-01-22 | actual | When the study began enrolling |
| Primary completion | 2025-11-03 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-03 | actual | The whole study's end, after follow-up |
| First posted | 2020-01-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cholangiocarcinoma
Intervention
- Drug: E7090
Primary outcome
what the primary-completion date above is the date OFORR
measured From first dose of study drug until disease progression, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 6 years 2 months)
Permalink · 4523.T's whole pipeline · Catalyst calendar · Every registered study · What changed